

BUILDING BRIDGES

AACI
Association of
American
Cancer Institutes

REPORT 2023

TABLE OF CONTENTS

- 1 A Message From AACI
- 2 Meetings
- 6 Initiatives and Programs
- 10 Awards
- 12 Public Policy
- 16 Sharing Best Practices
- 20 Supporters
- 23 Communications/
New Member
- 24 New Leadership
- 25 New Board Members
- 26 2023 Committees
- 28 2023 Members

OFFICERS

President

Caryn Lerman, PhD

USC Norris Comprehensive Cancer Center

Immediate Past President

Roy A. Jensen, MD

*The University of Kansas
Cancer Center*

Vice President/President-elect

Robert A. Winn, MD

VCU Massey Comprehensive Cancer Center

Treasurer

David M. Gosky, MA, MBA

*The Ohio State University
Comprehensive Cancer Center -
James Cancer Hospital and
Solove Research Institute*

Executive Director

Jennifer W. Pegher, MA, MBA

Association of American Cancer Institutes

Ruben A. Mesa, MD, FACP

*Atrium Health Wake Forest
Comprehensive Cancer Center*

Kunle Odunsi, MD, PhD

*The University of Chicago Medicine
Comprehensive Cancer Center*

Joann B. Sweasy, PhD

Fred & Pamela Buffett Cancer Center

Cornelia Ulrich, MS, PhD

*Huntsman Cancer Institute at the
University of Utah*

Robert H. Vonderheide, MD, DPhil

*Abramson Cancer Center of the
University of Pennsylvania*

NEW BOARD MEMBERS

Edward Chu, MD, MMS

*Montefiore Einstein
Comprehensive Cancer Center*

Raymond N. DuBois, MD

*Hollings Cancer Center
Medical University of South Carolina*

Yolanda Sanchez, PhD

*University of New Mexico
Comprehensive Cancer Center*


BOARD OF DIRECTORS

Marcia Cruz-Correa, MD, PhD

*University of Puerto Rico
Comprehensive Cancer Center*

Steven D. Leach, MD

*Dartmouth Cancer Center
Dartmouth College
Dartmouth Health*



On the cover: The Roberto Clemente Bridge, in Pittsburgh, home base of AACI.

Photo credits: Pages 2-6, 7 (audience), 9-11, 16-17, 19-20 Randy Belice; pages 12-13, 14 (group) Tyrone Bowie; page 15, Ollie Mae Nicholl for UMR; page 25, Montefiore Einstein Comprehensive Cancer Center/Jason Torres (Chu), Sarah Park (DuBois), Kata Sasvari (Sanchez)



Dr. Caryn Lerman
AACI President

Affectionately deemed “the city of bridges,” Pittsburgh is home to nearly 450 bridges, connecting the city’s diverse neighborhoods across three major rivers. Though AACI is headquartered in Pittsburgh, that is not the only reason we chose “building bridges” as the theme of this report. It’s also an apt summary of AACI’s work throughout 2023, in which the association served as a central hub linking cancer centers with government agencies, pharmaceutical and tech companies, cancer advocacy organizations, and—most importantly—each other.



Jennifer W. Pegher
AACI Executive Director

The past year saw the introduction of a new meeting and AACI presidential initiative – both focusing on “bridge-building” of a sort. In March, AACI co-hosted the inaugural Diversity, Equity, and Inclusion (DEI) Summit in partnership with the American Cancer Society and the Cancer Center DEI Network. The two-day event convened more than 80 attendees to discuss strategies for implementing DEI initiatives at their institutions. In September, a second DEI Summit was held in conjunction with the 2023 AACI/CCAF Annual Meeting. Attended by over 90 cancer center leaders, the summit allowed attendees to brainstorm methods for effective change, including external partnerships and public policy.

Also preceding the annual meeting, AACI hosted the second annual New Directors Meeting, which was attended by 30 cancer center directors. An offshoot of the Leadership Diversity and Development Initiative led by Dr. Caryn Lerman, the meeting provided a venue for a frank, open dialogue about a range of topics, including communicating and collaborating with institutional leaders.

Before taking the reins of the AACI presidency from Dr. Lerman, VCU Massey Comprehensive Cancer Center Director Dr. Robert A. Winn shared plans for his AACI presidential initiative dedicated to “inclusive excellence.” The initiative is focused on collaborative efforts to create opportunities for research, training and education, and patient navigation.

In 2023 AACI grew its network of collaborators, welcoming LSU LCMC Health Cancer Center and Prevent Cancer Foundation as cancer center and sustaining members, respectively. This was also a year of metaphorical bridge-crossing, marked by significant leadership transitions within the National Institutes of Health (NIH) and the National Cancer Institute (NCI), two agencies that are pillars of support within the United States’ cancer research ecosystem.

AACI endorsed the appointment of Dr. Monica Bertagnolli as the new director of the NIH, citing Dr. Bertagnolli’s comprehensive National Cancer Plan as a key example of her expertise. Just weeks later, AACI shared its enthusiastic support for President Biden’s nomination of Dr. W. Kimryn Rathmell as the 17th director of the NCI – and the second woman to fill the role. We look forward to continuing to work with the Biden administration, the NIH, and the NCI to advance our common goals.

We also look forward to continued partnerships with AACI’s members and corporate and nonprofit partners. Your steadfast support helps advance our mission of accelerating progress against cancer and promoting cancer health equity, and we thank you.

MEETINGS



2023 AACi Distinguished Scientist awardee Dr. Patricia LoRusso



2023 AACi/CGAF Annual Meeting global oncology panelists, L-R: Drs. Patrick Loehrer, Satish Gopal, Elias Melly, Martin Lajous



2023 AACI/CCAF ANNUAL MEETING

With a focus on promoting institutional diversity goals, nearly 500 cancer center colleagues, exhibitors, and supporters, representing 97 AACI member centers, gathered in Washington, DC, for the 2023 AACI/CCAF Annual Meeting. The three-and-a-half days of networking, presentations, and panel discussions underlined both the unique and complementary strengths of AACI’s member cancer centers, and the need to speak with a unified voice to optimize these attributes while accelerating progress against cancer.

The meeting opened on October 1 with a keynote presentation by **Dr. Philip E. Castle**, director of the National Cancer Institute’s (NCI) Division of Cancer Prevention (DCP). Dr. Castle provided an update on DCP initiatives, focusing on the benefits and challenges of cancer prevention; screening, including multi-cancer detection; and symptom management and care.

The meeting program was distinct in its breadth and depth. General sessions ranged from dismantling barriers to cancer care and enhancing diversity at AACI cancer centers, to research at basic science centers, the federal Advanced Research Projects Agency for Health (ARPA-H) program, and ways to improve protocol activation timelines.

A panel discussion led by incoming AACI President **Dr. Robert A. Winn**, examined the impact of the U.S. Supreme Court’s 2023 affirmative action ruling. Panelists were **Dr. David Acosta**, chief diversity and inclusion officer for the Association

of American Medical Colleges, and **Kevin Williams, Esq.**, director of the National Institutes of Health Office of Equity, Diversity, and Inclusion.

A session on ways to improve cancer center interactions with elected officials and federal agencies was moderated by **Erik Fatemi**, a principal with Cornerstone Government Affairs. Fatemi’s colleague, panelist **Laura Bozell**, urged cancer center leaders to develop long-term relationships with congressional staff since they are a key information conduit for legislators.

Dr. Patrick Loehrer, of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, moderated a session on global oncology, which included details on the NCI’s Global Oncology Survey.

The meeting’s final day included a presentation by **Dr. Ileana Hancu**, program manager for ARPA-H, and a session on clinical trial activation, moderated by **Dr. Suresh Ramalingam**, executive director of the Winship Cancer Institute of Emory University.

The meeting concluded with the NCI Director’s Report, delivered by NCI Principal Deputy Director **Dr. Douglas R. Lowy**, on behalf of NCI Director **Dr. Monica Bertagnolli**. Dr. Lowy emphasized both the need for cancer centers and their supporters to work together to battle cancer, and the interconnectedness of NCI’s budget and program components: research funding, training, and workforce development; resources for researchers; operating expenses; and cancer centers and clinical trials.



“Dismantling Barriers to Cancer Care” panel discussion, L-R: Dr. Kelvin Lee, Rae Ann Paden, Dr. Gary Puckrein, Dr. Rian Hasson, Dr. Debra Friedman



NCI Principal Deputy Director Dr. Douglas R. Lowy



Dr. Caryn Lerman passes the gavel to Dr. Robert A. Winn

PRESIDENTIAL TRANSITION

Dr. Caryn Lerman passed the gavel—and the AACI presidency—to Dr. Robert A. Winn at the close of the 2023 AACI/CCAF Annual Meeting. Dr. Lerman’s presidential initiative, focused on developing and diversifying cancer center leadership, will continue as a standing AACI program. AACI Executive Director Jennifer W. Pegher credited Dr. Lerman with her leadership and bringing a much-needed program to AACI.

Dr. Winn urged AACI members to help him achieve his ambitious goals for the association. His call to action echoed remarks by NCI Principal Deputy Director Dr. Douglas R. Lowy, who cited the African proverb, “If you want to walk fast, walk alone. If you want to walk far, walk together.”

INCLUSIVE EXCELLENCE PRESIDENTIAL INITIATIVE

AACI President Dr. Robert A. Winn’s presidential initiative aims to promote “inclusive excellence” by examining ways that AACI members can foster partnerships with like-minded organizations, government agencies, and other institutions. Dr. Winn introduced the plan at the 2023 AACI/CCAF Annual Meeting, starting with a review of AACI’s history and accomplishments. Noting how far the association has come in size, scope, and diversity since its founding in 1959, Dr. Winn acknowledged the significance of his presidency, saying, “I stand here today as the first person of color to be your president.”

In November, Dr. Winn traveled to the White House to meet with staff from the Office of the First Lady to discuss his presidential initiative, particularly its patient navigation component. Later that month, the initiative’s steering committee held its first meeting. Unique among AACI committees, the Inclusive Excellence Steering Committee includes two community advocates. These members bring valuable perspectives and experiences to the initiative.

Inclusive Excellence Steering Committee

Chair: Robert A. Winn, MD
VCU Massey Comprehensive Cancer Center

Wafik S. El-Deiry, MD, PhD, FACP
Legorreta Cancer Center at Brown University

Rudene Haynes, JD
Hunton Andrews Kurth LLP

Loriana Hernández-Aldama
ArmorUp for LIFE®


Robert S. Mannel, MD
Stephenson Cancer Center
University of Oklahoma

Stephen D. Nimer, MD
Sylvester Comprehensive Cancer Center
University of Miami

Ze’ev Ronai, PhD
Sanford Burnham Prebys
Medical Discovery Institute

Joann B. Sweasy, PhD
Fred & Pamela Buffett Cancer Center

Cornelia Ulrich, MS, PhD
Huntsman Cancer Institute at the
University of Utah





Cancer center leaders at the New Directors Meeting

NEW DIRECTORS MEETING

The day before the 2023 AACI/CCAF Annual Meeting, 30 cancer center directors attended AACI's second annual New Directors Meeting. The program featured a series of panel discussions to prepare the new directors for their leadership roles, with experienced directors offering their perspectives on challenges—and opportunities—that all centers face. Conversation topics included how to enhance the impact of clinical research at cancer centers, how clinical trials offices work with their centers, and advice on effective collaboration.

DIVERSITY, EQUITY, AND INCLUSION SUMMIT

In partnership with the American Cancer Society and the Cancer Center DEI Network, AACI co-hosted the inaugural Diversity, Equity, and Inclusion (DEI) Summit in March. The two-day event convened cancer center leaders, researchers, and administrators to share insights on how institutions are enhancing DEI efforts, and to address barriers that cancer centers face in implementing DEI initiatives.

With over 80 individuals participating, the summit featured sessions on advancing a culture of institutional excellence and approaches to managing data and metrics reporting requirements in the Plan to Enhance Diversity section of the NCI's Cancer Center Support Grant (CCSG) application. In September, a second DEI Summit was held preceding with the 2023 AACI/CCAF Annual Meeting. The meeting included panel sessions on ways that cancer centers can enhance partnerships with Historically Black Colleges and Universities, Hispanic-Serving Institutions, and Minority-Serving Institutions, and how states are navigating policy changes related to DEI.

Attended by over 90 cancer center leaders, the summit concluded with a brainstorming session for cancer center directors and DEI experts with the goal of effecting positive change at their institutions.

15TH ANNUAL AACI CLINICAL RESEARCH INNOVATION (CRI) MEETING

AACI's Clinical Research Innovation (CRI) provides a network for cancer center clinical research leaders to share best practices around clinical trials office operations. The 15th Annual AACI CRI Meeting drew almost 500 in-person attendees and 71 virtual, representing 83 cancer centers. Attendees included clinical research office leaders, medical directors, cancer center administrators, patient advocates, and representatives from government and industry.

Several meeting sessions focused on collaboration and building solid teams in the clinical trials office (CTO) and expanding clinical trials in the community. Other meeting topics included diversity, equity, and inclusion; artificial intelligence in oncology; communication gaps between clinical care and research operations; and preparing for the NCI's CCSG application process. Please see page 7 for more on CRI.



Attendees at the second Diversity, Equity, and Inclusion (DEI) Summit, in September





AACI's initiatives and programs provide platforms for managing member services and activities that offer numerous opportunities for interactions with AACI and among cancer center leaders and staff.

CLINICAL RESEARCH INNOVATION (CRI)

CRI's mission is to collect, evaluate, and share best practices that promote the efficient and effective operation of cancer clinical research offices, and to interact with key stakeholders to inform policy decisions and advocate for improvement in the national clinical trials enterprise.

Highlights of the year included publication of a paper in *JNCI Cancer Spectrum*, focused on the impact of COVID-19 on cancer center workload. The study was authored by **Drs. Thomas J. George, Jr.; Tara L. Lin; and Theresa L. Werner** and 10 past and present CRI steering committee members. An AACI white paper, developed in conjunction with AACI Corporate Roundtable partners, provided recommendations on how to improve trial activation timelines.



Dr. Thomas J. George, Jr.
CRI Steering Committee Chair-elect



Dr. Tara L. Lin
CRI Steering Committee Chair

To establish metrics and measure growth in clinical trials offices (CTO), a benchmarking survey examining budgets, accruals, staffing, and other CTO components was distributed to AACI members in May with the goal of publishing findings in early 2024.

CRI also oversees a portfolio of programs aimed at improving cancer center clinical trial operations:

CRI Education and Operations Subcommittee

The Education and Operations Subcommittee provides a platform to discuss CTO challenges related to education and training. In 2023, the subcommittee identified gaps in competencies for oncology research staff and created a template for using Attributable, Legible, Contemporaneous, Original, and Accurate (ALCOA+) principles for good documentation practices. A template was also developed to better identify and report protocol deviations. Beginning in 2024, these templates will be available in the AACI resource library for members to use when onboarding employees or assessing their competencies.

CTO Medical Directors, CTO Administrative Directors, and Associate Directors of Clinical Research Forums

CTO administrative and medical directors held roundtables every other month as well as quarterly discussions with their respective groups. The Associate Directors of Clinical Research Forum launched in 2023 and meets bimonthly. The first major task of the new forum is to draft a standardized job description for the role.



Clinical research colleagues gather to share best practices at the AACI CRI annual meeting

INITIATIVES AND PROGRAMS

CAR T INITIATIVE

AACI's CAR T Initiative convenes cancer center clinicians and administrators to discuss challenges and offer best practices for managing and developing a CAR T therapy program. Collaboration is facilitated by topic-specific working groups, webinars, listserv discussions, monthly update calls, and in-person meetings. Participants include staff and faculty at AACI member institutions.

In 2023, CAR T Steering Committee members developed educational resources to increase patient referrals for CAR T therapy by community physicians. Additionally, the steering committee partnered with the American Society for Transplantation and Cellular Therapy (ASTCT), the Association of Community Cancer Centers (ACCC), and Kite Pharma to develop a framework to enable community oncology care teams to assess patients more easily for CAR T consultation. A summary of the group's discussion, and a description of the framework, co-authored by AACI, ASTCT, and ACCC, was published in the ASTCT journal, *Transplantation and Cellular Therapy*.



Dr. Peter Riedell
CAR T Steering Committee Chair



Dr. Leonidas C. Platanias
CTO Staff Retention Task Force Chair

CTO STAFF RETENTION TASK FORCE

Established in response to the mass resignation of CTO staff amid the COVID-19 pandemic, the CTO Staff Retention Task Force is led by **Dr. Leonidas C. Platanias**, director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. To assess the scope of the CTO staffing challenge at AACI cancer centers, the task force distributed surveys to cancer center directors in 2022 and again in 2023. Survey results were published in a report, available to AACI members, highlighting key data from the two surveys and successful staff retention strategies implemented by AACI cancer centers.

PHYSICIAN CLINICAL LEADERSHIP INITIATIVE (PCLI)

The PCLI Steering Committee is a resource for creating best practices as well as for comparing approaches to common problems facing clinical physician leaders, including deputy directors, chief medical officers, physicians-in-chief, and similarly titled positions. PCLI's 11th annual meeting, held during the AACI/CCAF annual meeting, featured a panel discussion titled "Bridging the Divide Between Cancer Centers and Cancer Service Lines." The meeting featured preliminary results of a survey on cancer service line reporting and financial structure at member cancer centers.



Dr. Karen L. Reckamp
PCLI Steering Committee Chair



CRI Steering Committee



AWARDS



Dr. Patricia LoRusso with
AACI Board of Directors member
Dr. Joann B. Sweasy



Dr. Amelie Ramirez with AACI
Board of Directors member
Dr. Ruben Mesa



Dana Dornsife with AACI President
Dr. Caryn Lerman



U.S. Senator Amy Klobuchar (D-MN) and
U.S. Representative Neal Dunn (R-FL)



Four AACI awards were presented at the 2023 AACI/ CCAF Annual Meeting, in recognition of outstanding support and achievement in the cancer research community.

AACI DISTINGUISHED SCIENTIST AWARD

Dr. Patricia LoRusso, leader of the Early Phase Clinical Trials Division at Yale Cancer Center and Smilow Cancer Hospital, received AACI's Distinguished Scientist Award. She presented a moving personal account of her clinical research career.

AACI CHAMPION FOR CURES AWARD

Dana Dornisfe, founder and chief mission and strategy officer of the Lazarex Cancer Foundation, was honored with the AACI Champion for Cures Award. Her philanthropy supports community outreach and engagement efforts to increase access to cancer care and clinical trials in minority and disadvantaged communities.

The AACI Champion for Cures Award was established in 2018 to recognize one or more people, who, through direct financial support of an AACI cancer center, demonstrate exceptional leadership in advancing cancer research and care and in inspiring others to do the same.

AACI CANCER HEALTH EQUITY AWARD

The Cancer Health Equity Award went to **Dr. Amelie Ramirez**, chair of the Department of Population Health Sciences at UT Health San Antonio. As leader of the community outreach and engagement team at Mays Cancer Center, Dr. Ramirez has

implemented changes that have improved equity and diversity in cancer clinical trial recruitment. Established in 2021, the Cancer Health Equity Award recognizes an individual or group who demonstrates exceptional leadership in promoting health equity, mitigating cancer disparities, and advocating for diversity and inclusion at their cancer center.

AACI PUBLIC SERVICE AWARD

AACI's Public Service Award was presented to **U.S. Senator Amy Klobuchar (D-MN)** and **U.S. Representative Neal Dunn (R-FL)**. In accepting her award, Sen. Klobuchar assured attendees that their work does not go unrecognized by Congress. "There are people who have your backs and see you as the pinnacle of what needs to be done," she said. Rep. Dunn commented on the "unbelievable advances" in cancer treatment and reminded attendees not to hide their work from legislators.

The AACI Public Service Award was established in 2003 to recognize public servants who are dedicated supporters of the National Institutes of Health (NIH), the National Cancer Institute (NCI), and cancer centers in their respective states.



Attendees from Florida cancer centers with Rep. Neal Dunn (second from left)



Attendees from Minnesota cancer centers with Sen. Amy Klobuchar (second from left)



AACI 2023 Spring Government Relations Forum attendees at Huntsman Cancer Institute, in Salt Lake City

By leveraging the collective efforts of cancer centers across North America, AACI has unprecedented opportunities to exert influence on public policy related to cancer research.

AACI's public issues work is primarily guided by its Government Relations (GR) Steering Committee, which coordinates activity at AACI cancer centers to educate legislators about the cancer research community and its positive impact on patients. AACI hosts monthly Zoom meetings with cancer center GR colleagues and expert guests on federal issues impacting the cancer centers, while AACI's Public Policy Resource Library shares cancer-related legislation at the state level and tracks AACI-endorsed federal legislation.

GOVERNMENT RELATIONS FORUM

In March, AACI held its Spring GR Forum at Huntsman Cancer Institute at the University of Utah. The forum gathered AACI staff, government relations representatives from AACI cancer centers, and sustaining members, and included a tour of the Huntsman campus and updates from the center's leadership and

clinical trials office (CTO). Topics discussed included opportunities for collaboration between GR staff and their centers' community outreach and engagement colleagues and CTOs. In addition, congressional staffers from Huntsman's catchment area and representatives from the National Cancer Institute's (NCI) Office of Government and Congressional Relations provided updates.



L-R: Dr. Philip Greenberg, Dr. Ruben Mesa, Dr. Roy S. Herbst, Jennifer Pegher, and Jon Retzlaff meet with staff for Sen. Patty Murray (D-WA)



HILL DAY

In May, AACI co-hosted its annual joint Hill Day with the American Association for Cancer Research (AACR). The first in-person visit to Capitol Hill since 2019 attracted 85 participants from 27 states, including cancer center directors, researchers, oncologists, cancer survivors, and other advocates. The group met with congressional legislators and staff, presenting a unified voice in support of stable funding increases for the National Institutes of Health (NIH) and NCI.

The event kicked off the evening before with a reception at the Rayburn House Office building. **U.S. Representatives Derek Kilmer (D-WA) and Kathy Castor (D-FL)** attended, and **Rep. Debbie Wasserman Schultz (D-FL)** delivered remarks after receiving AACI's Cancer Research Ally Award. An additional Ally award, to **Rep. Brian Fitzpatrick (R-PA)**, was accepted on his behalf by Legislative Assistant **Jacqueline Baggett**.

Recipients of AACI's Hill Day Scholarship were among the patient advocates in attendance. Representing Florida, Illinois, Kansas, New York, and Wisconsin, these advocates shed light on cancer's far-reaching impact. Their unique and compelling stories underscored the vital need for continued funding for the NIH and the NCI.

Hill Day assumed heightened importance against the backdrop of contentious legislative debate over raising the federal budget debt ceiling.



Left to Right: Dr. Jonathan D. Licht, Rep. Debbie Wasserman Schultz (D-FL), AACI Executive Director Jennifer W. Pegher



Specific budgetary “asks” for 2023's Hill Day were \$50.924 billion, an increase of \$3.465 billion, for the NIH in Fiscal Year 2024, and at least \$9.988 billion, an increase of \$2.6 billion, for the NCI to support additional cancer research grants, as requested in the NCI Director's Professional Judgment Budget.

Above: Representing the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, L-R: Karen Lambert, Attia Smith and Kellie Jack



2023 AACI/AACR Hill Day attendees



Dr. Monica Bertagnolli

NEW NCI AND NIH DIRECTORS

Two of the nation's premier federal scientific agencies welcomed new leaders in 2023.

President Joe Biden named **Dr. W. Kimryn Rathmell** as the next director of the National Cancer Institute (NCI) in November, following **Dr. Monica Bertagnolli's** confirmation as the new director of the National Institutes of Health (NIH). Dr. Bertagnolli had served a year-long tenure as NCI's first female director.



Dr. W. Kimryn Rathmell

Dr. Rathmell was the Hugh Jackson Professor of Medicine and chair of the Department of Medicine at Vanderbilt University Medical Center (VUMC), joining VUMC in 2015 as director of the Division of Hematology and Oncology.

"Dr. Rathmell's background in cancer research and institutional leadership will be a great benefit to AACI's members as well as cancer patients and the wider oncology community," AACI Executive Director **Jennifer W. Pegher** said.



AACI ADVOCACY IN THE NATION’S CAPITAL

Throughout the year, AACI participated in numerous advocacy events, including those highlighted here.

The gatherings were hosted by like-minded partners and cancer centers, including the American Cancer Society Cancer Action Network, the Coalition for Health Funding, Friends of Cancer Research, One Voice Against Cancer (OVAC), and United for Medical Research (UMR).

In the spring, AACI participated in OVAC’s Grassroots Hill Day, and AACI Senior Government Relations Manager **Jaren Love** joined United for Medical Research (UMR) staff to meet with new House Appropriations Labor, Health and Human Services, Education Subcommittee Chair, **Rep. Robert Aderholt (R-AL)**. AACI also teamed up with UMR to meet with staffers from the offices of **Sen. Jerry Moran (R-KS)** and **Rep. Guy Reschenthaler (R-PA)** to advocate for robust annual increases to the NIH budget as a collective of the research community, patient and health advocates and industry.

Other advocacy activities included uniting with the Coalition to Improve Access to Cancer Care to meet with Members of Congress to seek support for the Cancer Drug Parity Act. In addition, AACI participated in the Rally for Medical Research and led a group of advocates to meet with representatives and staff for two senators.

The Hematology/Oncology Pharmacy Association (HOPA), an AACI sustaining member, gathered representatives from 20 professional and patient advocacy organizations to discuss policy solutions for ongoing chemotherapy drug shortages.

OVAC’s Hill Day gave AACI the opportunity to help deliver a targeted message to congressional appropriations committee leaders and members, urging increased funding for NIH, NCI, and the Centers for Disease Control and Prevention, and to underscore the need to pass a Fiscal Year 2024 budget.

Later in the year, UMR introduced its report, “How NIH-Funded Research Benefits Rural States,” on Capitol Hill. As a UMR board member, AACI’s Jaren Love participated in the report’s rollout. The event included a panel discussion with patients and representatives from industry and academia, and **Rep. Steve Womack (R-AR)** and **Sen. Shelley Moore Capito (R-WV)** shared the impact of NIH funding in their respective states. Love also attended the Senate confirmation hearing of **Monica Bertagnolli, MD**, as the new director of the NIH.

In November, AACI participated in the Friends of Cancer Research Annual Meeting, advocated for the PREVENT HPV Cancers Act at the HPV Cancers Alliance Hill Day, and attended a press conference on Capitol Hill in support of the bipartisan Increasing Access to Lung Cancer Screening Act.



Rep. Steve Womack (R-AR)



Sen. Shelley Moore Capito (R-WV)

PUBLIC POLICY RESOURCE LIBRARY AND FEDERAL LEGISLATION TRACKER

AACI continues to update its Public Policy Resource Library and provide updates on all AACI-endorsed federal legislation. As of late 2023, AACI is tracking 13 bills covering issues such as clinical trial diversity, increased funding for cancer research, and expanding access to cancer prevention measures.

SHARING BEST PRACTICES





Providing a platform to share best practices is one of AACI's signature member services. With the singular aim of improving cancer center operations and patient care, AACI educates the oncology workforce through listservs, webinars, and poster and abstract presentations.

POSTERS AND ABSTRACTS

The 15th Annual AACI Clinical Research Innovation (CRI) Meeting featured 118 abstracts from 36 cancer centers. Abstract topics spanned several areas of clinical trial operations, including quality assurance, community outreach and engagement, and trial start-up and activation. Three winning abstracts were presented individually during the meeting:

FIRST PLACE: Hybrid Decentralization of Early Phase Cancer Clinical Trials to Enhance Study Recruitment of Underrepresented Minorities


C. Wiess, A. Rodrigues, I. Palma, D. Wall, P. LoRusso
Yale Cancer Center
Yale School of Medicine

SECOND PLACE: Strategies to Improve Clinical Research Staff Engagement, Retention, Career Development, and Performance at an NCI-Designated Cancer Center

C. Spalink, A. Joshi, A. Husni, P. Patel, A. Haegler, E. Waalkes, N. Chowdhury, B. Pothuri, J. Mehnert
Laura and Isaac Perlmutter Cancer Center at NYU Langone

THIRD PLACE: Protocol Prioritization Scores: Are They Predictive?

J. Bollmer, J. Thomas, B. George, M. Larson, K. Schroeder, S. Zindars, R. Kurzrock
Medical College of Wisconsin Cancer Center



AACI cancer centers in Florida were well-represented at the CRI annual meeting. Preceding page: Sylvester Comprehensive Cancer Center, University of Miami (top); Moffitt Cancer Center. Above: University of Florida Health Cancer Center.

LISTSERVS

In 2023, AACI launched an **Associate Director for Clinical Research** listserv. It joined several existing platforms for cancer center colleagues to ask questions, discuss challenges, and share best practices.

The **Clinical Research Innovation (CRI)** listserv continues to grow since its inception in 2010, with representation standing at approximately 1,200 users from 90 cancer centers. Topics discussed in 2023 included staff retention; acuity tools and job metrics; DSMC monitoring; eligibility waivers; serious adverse event reporting; and medical coverage analysis for clinical trials.

More than 250 **community outreach and engagement (COE)** professionals at AACI cancer centers continue to post queries or otherwise reach out to colleagues about COE-related topics on the COE listserv.

AACI's **Catchment Area Research and Data Science (CARDS)** listserv is building a supportive and collaborative community for those involved in cancer center data collection, analysis, and utilization. CARDS is for individuals engaged in community outreach, biostatistics, cancer informatics and similar roles in AACI cancer centers.

The **CTO Medical Directors** and **CTO Administrative Directors** listservs provide forums for clinical trials office leaders to discuss their roles and workplaces and to create mentoring opportunities.

SHARING BEST PRACTICES



Dr. Sean Davis



Dr. Christopher Lieu

WEBINARS

AACI's Physician Clinical Leadership Initiative (PCLI) hosted two webinars in 2023:

◀ **“Seismic Shift or Small Step Forward? Artificial Intelligence and its Impact on Cancer Care and Research”** shared new advances in artificial intelligence and machine learning and its impact on cancer care and research. Panelists were **Dr. Christopher Lieu**, University of Colorado Cancer Center and **Dr. Sean Davis**, University of Colorado Anschutz School of Medicine.



Dr. Julie Vose



Dr. Laura Tenner

◀ **“A Practical Approach to Building a Survivorship Program”** was presented by **Dr. Julie Vose**; **Dr. Laura Tenner**; and **Rachael Schmidt**, University of Nebraska Medical Center. The webinar reviewed core aspects of a survivorship program and considerations to make it sustainable.



Rachael Schmidt





SUPPORTERS





The 2023 AACI/CCAF Annual Meeting and the 15th Annual Clinical Research Innovation (CRI) Meeting provided opportunities for supporters to interact with AACI members and representatives from cancer research-related organizations.

Supporters and exhibitors promoted their products and services to hundreds of meeting attendees including cancer center directors, executive administrators, and leaders of clinics, laboratories, and specialized research facilities.

AACI received support in 2023 for its events and programs from:

- Actalent
- Adminformatics
- Advarra
- American Society of Clinical Oncology
- Astound Research
- Caris Life Sciences
- Deep 6 AI
- ECG Management Consultants
- Florence Healthcare
- Huron
- Idea Elan
- Inspirata
- Integra Connect
- Merck
- Mint Medical
- Novartis
- Pfizer
- Slope
- The Ohio State University Comprehensive Cancer Center - The James
- Triomics
- Varian Medical Systems
- VCU Massey Comprehensive Cancer Center
- Veeva Systems
- Verily Life Sciences
- Vitalief
- WCG
- WellSky
- Yunu, Inc.


EXHIBITORS AT THE 15TH ANNUAL CRI MEETING

- Actalent
- Advarra
- Deep 6 AI
- Florence Healthcare
- Huron
- Mint Medical
- Triomics
- Veeva
- Verily Life Sciences
- Vitalief
- WCG
- WellSky
- Yunu, Inc.

EXHIBITORS AT THE 2023 AACI/CCAF ANNUAL MEETING

- Advarra
- Caris Life Sciences
- Concert AI
- Deep 6 AI
- ECG Management Consultants
- Florence Healthcare
- Huron
- Idea Elan
- Inspirata
- Integra Connect
- Triomics
- Verily Life Sciences
- Vitalief
- WCG
- Yunu, Inc.

AACI appreciates the valuable contributions that these supporters make to fulfilling the association’s mission of enhancing the impact of leading academic cancer centers.



SUPPORTERS



A Member of the Roche Group



PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*



A GILEAD Company



CORPORATE ROUNDTABLE

The AACI Corporate Roundtable provides a forum for AACI cancer centers to address topics of mutual interest with industry colleagues. These interactions lead to support for both new and ongoing AACI programs and initiatives. Roundtable members met in June during the 15th Annual Clinical Research Innovation (CRI) Meeting and again in October at the 2023 AACI/CCAF Annual Meeting. Discussions focused on areas such as clinical trial access and diversity; centralized monitoring to reduce on-site monitoring visits; operational efficiencies; partnerships to increase clinical trial access; and CTO staff retention. AACI extends its gratitude for the commitment and support of its 2023 Corporate Roundtable members shown at left.

SUSTAINING MEMBERS

AACI welcomed Prevent Cancer Foundation as a new Sustaining Member in 2023. Sustaining membership in AACI includes nonprofit organizations that represent and support the educational and professional development of clinical oncology health professionals and researchers. These like-minded cancer organizations and patient advocacy groups share a common goal of decreasing the national cancer burden. Sustaining members participate in AACI-sponsored meetings, workshops, and forums and meet annually with



American Association
for Cancer Research



Hematology/Oncology
Pharmacy Association




Society for Immunotherapy of Cancer

Building bridges to other organizations that share our cancer advocacy goals is an essential component of AACI’s mission. In the communications realm, enhancing partnerships with our cancer center members included AACI’s sponsorship of the 2023 NACCCO-PAMN Conference—a collaboration by the National Association of Cancer Center Development Officers and the Public Affairs and Marketing Network—hosted by Winship Cancer Institute of Emory University, in Atlanta.

AACI has enjoyed a long-standing relationship with PAMN, a cooperative venture of academically based comprehensive, clinical, basic, and consortium cancer centers as designated by the National Cancer Institute (NCI) or that are members of AACI. PAMN works closely with the NCI’s Office of Media Relations and Public Affairs to further public awareness of cancer research, prevention, detection, and treatment. PAMN members are frequent

contributors to AACI’s monthly newsletter, AACI Update, and they suggest topics for consideration for AACI’s monthly editorial series, AACI Commentary.

AACI is a frequent contributor to *The Cancer Letter* (TCL), a weekly news publication on issues that shape oncology. In 2023, TCL published statements from the association regarding cancer-related aspects of President Biden’s State of the Union address and his proposed budget for 2024. It also covered the introduction of AACI President Dr. Robert A. Winn’s presidential initiative. In addition, TCL ran excerpts from the February 2023 AACI Commentary (insights on cancer center leadership by Dr. George J. Weiner) and a 2021 history of AACI, supplemented its Cancer History Project archives with the keynote presentation from the 2022 AACI/CCAF Annual Meeting; highlighted



a report by AACI’s CTO Staff Retention Task Force on staff retention at clinical trials offices; and quoted the authors of AACI’s June 2023 Commentary regarding the U.S. Supreme Court’s ruling on LGBTQ+ rights.



Dr. Joe W. Ramos

NEW MEMBER

LSU LCMC Health Cancer Center

In January, AACI welcomed its newest member, LSU LCMC Health Cancer Center. **Dr. Joe W. Ramos** is the center’s director.

The LSU LCMC Health Cancer Center, located in New Orleans, Louisiana, was established in 2021. LSU Health and LCMC Health have each committed \$50 million to the LSU LCMC Health Cancer Center aimed at changing the trajectory

of cancer prevention, detection, and treatment throughout the state. That investment, and subsequent additional funding, supports LSU’s journey to NCI designation through expanded cancer-focused research and multidisciplinary care programs. LSU Health is a member of the Louisiana Cancer Research Center and the intended eventual NCI Designation applicant.



Dr. Robert A. Winn

AACI PRESIDENT

Dr. Robert A. Winn, director of VCU Massey Comprehensive Cancer Center, is AACI's new president. He will serve a two-year term, after succeeding **Dr. Caryn Lerman**, director of the USC Norris Comprehensive Cancer Center, at the close of the 2023 AACI/CCAF Annual Meeting in October. Overseeing a cancer center comprised of nearly 150 scientists and clinical investigators, Dr. Winn is leading the nation in establishing a 21st-century model for promoting diversity, equity, and inclusion in the oncology workforce; spearheading interdisciplinary approaches to cancer disparities research; and building trust among populations previously disenfranchised from health care. Dr. Winn's AACI Presidential

Initiative aims to develop and promote inclusive excellence by examining methods through which AACI members can foster partnerships with like-minded organizations, government agencies, and other institutions – regionally, nationally, and globally.

Activities proposed for the Inclusive Excellence Initiative focus on collaborative efforts to create opportunities for research, training and education, and patient navigation. The initiative will also support the continued facilitation of AACI's annual Leadership Diversity and Development Workshop and the annual Diversity, Equity, and Inclusion (DEI) Summit in partnership with the Cancer Center DEI Network and the American Cancer Society.



Dr. Joann B. Sweasy

AACI PRESIDENT-ELECT

Dr. Joann B. Sweasy, director of the Fred & Pamela Buffett Cancer Center, was elected by the AACI membership to serve a two-year term as vice president/president-elect of AACI's Board of Directors.

Dr. Sweasy was appointed director of the Buffett Cancer Center at the University of Nebraska in 2023. Previously, she served as director of the University of Arizona Cancer Center, leading it to redesignation as a National Cancer Institute

(NCI)-Designated Comprehensive Cancer Center. She also served as the associate director for basic sciences and co-leader of the Radiobiology and Radiotherapy Program at the Yale Cancer Center.

Dr. Sweasy is an internationally recognized expert in the genetics, cell biology, and biochemistry of DNA repair, and has been continuously funded by the National Institutes of Health since 1994. She was appointed to AACI's board in 2021.

AACI BOARD WELCOMES THREE CANCER CENTER LEADERS

Drs. Edward Chu, Raymond DuBois, and Yolanda Sanchez, were elected to AACI's Board of Directors in 2023.



Dr. Edward Chu

Dr. Chu is director of the Montefiore Einstein Comprehensive Cancer Center, leading its recent successful renewal and designation as an NCI Comprehensive Cancer Center. He is an international expert in investigating the mechanisms of cellular resistance to the fluoropyrimidines and antimetabolites and has also played a leading role in cancer drug development and early-phase clinical trials focused on colorectal cancer and other GI cancers.



Dr. Raymond N. DuBois

Dr. DuBois leads Hollings Cancer Center, Medical University of South Carolina. His research has made significant contributions to understanding the role of inflammation and inflammatory mediators in the progression of colon cancer and other gastrointestinal malignancies. Among his many awards and honors, Dr. DuBois is a member of the National Academy of Medicine and a fellow of the American Association for the Advancement of Science.



Dr. Yolanda Sanchez

Dr. Sanchez is director and CEO of the University of New Mexico Comprehensive Cancer Center. She is an international expert in DNA damage response pathways and her work focuses on exploring oncology targets and drug development for clinical trials. Throughout her career, Dr. Sanchez has prioritized collaboration across basic science, population science, and clinical research, and mentored trainees and junior faculty to help them develop successful research careers.

OUTGOING BOARD MEMBERS

AACI extends its appreciation for service on AACI's Board of Directors to **Dr. Roy A. Jensen**, director of The University of Kansas Cancer Center, and **Dr. Cornelia Ulrich**, chief scientific officer and executive director, comprehensive cancer center, Huntsman Cancer Institute at the University of Utah. AACI's new vice president/president-elect, **Dr. Joann B. Sweasy**, also finished her term as a regular AACI board member in 2023.



Dr. Roy A. Jensen



Dr. Cornelia Ulrich

2023 COMMITTEES



ANNUAL MEETING PROGRAM COMMITTEE

Chair: Primo N. Lara, Jr., MD
UC Davis Comprehensive Cancer Center

Edward Chu, MD, MMS
Montefiore Einstein Comprehensive Cancer Center

Hannah Hazard-Jenkins, MD
WVU Cancer Institute

Matthew Huesser, MBA, DBA
Sidney Kimmel Cancer Center at Jefferson Health

Kelvin Lee, MD
Indiana University Melvin and Bren Simon
Comprehensive Cancer Center

Michelle Lin, MBA
VCU Massey Comprehensive Cancer Center

Rae Ann Paden, MPH
University of New Mexico Comprehensive Cancer Center

Jennifer W. Pegher, MA, MBA
Association of American Cancer Institutes

John Pounardjian, MBA
Case Comprehensive Cancer Center

Suresh Ramalingam, MD
Winship Cancer Institute of Emory University

Matthew Vander Heiden, MD, PhD
Koch Institute for Integrative Cancer Research at MIT

CAR T STEERING COMMITTEE

Chair: Peter Riedell, MD
The University of Chicago Medicine
Comprehensive Cancer Center

Lihua Elizabeth Budde, MD, PhD
City of Hope Comprehensive Cancer Center

Matthew H. Carabasi, MD
Sidney Kimmel Cancer Center at Jefferson Health

Natalie Grover, MD
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Yen-Michael S. Hsu, MD, PhD, CABP
UPMC Hillman Cancer Center

Frederick L. Locke, MD
Moffitt Cancer Center

Premal Lulla, MD
Dan L. Duncan Comprehensive Cancer Center at
Baylor College of Medicine

Joseph McGuirk, DO, FACP
The University of Kansas Cancer Center

Kunle Odunsi, MD, PhD
The University of Chicago Medicine
Comprehensive Cancer Center

Sheila Ouverson, MPA
Holden Comprehensive Cancer Center
University of Iowa

Sapna Parshottam, BSc, MSc
The University of Texas MD Anderson Cancer Center

Miguel-Angel Perales, MD
Memorial Sloan Kettering Cancer Center

David L. Porter, MD
Abramson Cancer Center of the
University of Pennsylvania

Craig Sauter, MD
Cleveland Clinic Cancer Center

Joseph Uberti, MD, PhD
Karmanos Cancer Institute
Wayne State University

CLINICAL RESEARCH INNOVATION (CRI) STEERING COMMITTEE

Chair: Tara L. Lin, MD
The University of Kansas Cancer Center

Chair-elect: Thomas J. George, Jr., MD, FACP
University of Florida Health Cancer Center

Frances Brogan, MSN, RN, OCN, CCRP
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center

Arcadia Cruz, PhD
UC San Diego Moores Cancer Center

Angela Fritsche, MPA
Mayo Clinic Comprehensive Cancer Center

Margaret Kasner, MD, MSCE
Sidney Kimmel Cancer Center at Jefferson Health

Matthew R. Kovak, MS, CCRP
UAMS Winthrop P. Rockefeller Cancer Institute

Wendy Law, PhD
Fred Hutchinson Cancer Center

Christopher Loertscher, MA
USC Norris Comprehensive Cancer Center

Eneida Nemecek, MD, MS, MBA
OHSU Knight Cancer Institute

Jennifer W. Pegher, MA, MBA
Association of American Cancer Institutes

Anne Schnatterly, MBA, BSN, RN, CCRP
WVU Cancer Institute

Susanna Sellmann, MRT, BSc, CCRP
Princess Margaret Cancer Centre
University Health Network

Rachna Shroff, MD, MS
The University of Arizona Cancer Center

CRI BENCHMARKING SURVEY WORKING GROUP

Chair: Tara L. Lin, MD
The University of Kansas Cancer Center

Frances Brogan, MSN, RN, OCN, CCRP
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center

Arcadia Cruz
UC San Diego Moores Cancer Center

Angela Fritsche, MPA
Mayo Clinic Comprehensive Cancer Center

Thomas J. George, Jr., MD, FACP
University of Florida Health Cancer Center

Margaret Kasner, MD, MSCE
Sidney Kimmel Cancer Center at Jefferson Health

Matthew R. Kovak, MS, CCRP
UAMS Winthrop P. Rockefeller Cancer Institute

Carrie Lee, MD
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Ji-Hyun Lee, DrPH
University of Florida Health Cancer Center

Man Chong "Henry" Leong, PhD
University of Florida, Department of Biostatistics

Christopher Loertscher, MA
USC Norris Comprehensive Cancer Center

CRI EDUCATION AND OPERATIONS SUBCOMMITTEE

**Subcommittee Leader:
Wendy Bloomer, PhD, CCRP**
Duke Cancer Institute, Duke University Medical Center

Elizabeth Anderson, MPH, MBA
Stanford Cancer Institute

Jonathan Aguilar
The University of Texas MD Anderson Cancer Center

Vanessa Cajahuaringa, CCRP
Cedars-Sinai Cancer

Erin Cebula, MPH, CCRP
Wilmot Cancer Institute, UR Medicine

Doreen DeGray
Wilmot Cancer Institute, UR Medicine

Jilliann De Jong, CCRP
The University of Kansas Cancer Center

Chloe Fournier, MBA, CCRP
Duke Cancer Institute, Duke University Medical Center

Krista French, CCRC
Wilmot Cancer Institute, UR Medicine

Katie Hogan
University of Colorado Cancer Center

Mary Horak, CCRP
UPMC Hillman Cancer Center

Christine Jerome, MS, CCRP
Sidney Kimmel Cancer Center at Jefferson Health

Fyalon Kerr, CCRP
Indiana University Melvin and Bren Simon
Comprehensive Cancer Center

Rachel Kingsford, MS, CCRP
Huntsman Cancer Institute at the University of Utah

Stacey Lewis, RN, BSN, OCN, BBA
Atrium Health Wake Forest Baptist
Comprehensive Cancer Center

Erin E. Lynch, MS, CCRP
Dartmouth Cancer Center

Holly McClellan
Vanderbilt-Ingram Cancer Center

Mimi McKay, MPH, BSN, RN, CCRP
Holden Comprehensive Cancer Center
University of Iowa

Cary Passaglia, MSRC, CCRP
Robert H. Lurie Comprehensive Cancer Center of
Northwestern University

**Yolanda Pitts, MD**

Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

Jacqueline Stern, MD

Vanderbilt-Ingram Cancer Center

Claire Sulkowski, CCRP

Dana-Farber Cancer Institute
Harvard Medical School

Ginnette Watkins-Keller, DNP, RN, OCN

Rutgers Cancer Institute of New Jersey

Schantel Williams

The Tisch Cancer Institute at Mount Sinai

**CLINICAL TRIALS OFFICE (CTO)
STAFF RETENTION TASK FORCE****Chair: Leonidas C. Platanius, MD, PhD**

Robert H. Lurie Comprehensive Cancer Center of
Northwestern University

Philip Arlen, PhD

Sylvester Comprehensive Cancer Center
University of Miami Health System

Zeno Ashai, MBBS, MPH

USC Norris Comprehensive Cancer Center

Frances Brogan, MSN, RN, OCN, CCRP

Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center

Craig Bunnell, MD, MPH, MBA

Dana-Farber Cancer Institute
Harvard Medical School

Andrew Chapman, DO, FACP

Sidney Kimmel Cancer Center at Jefferson Health

David Gosky, MA, MBA

The Ohio State University Comprehensive Cancer Center
- James Cancer Hospital and Solove Research Institute

Andrew Lassman, MD

Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center

Carrie Lee, MD, MPH

UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Kristie Moffett, MHA

Moffitt Cancer Center

Suresh Ramalingam, MD

Winship Cancer Institute of Emory University

Dedra Schendzielos, MHA

Masonic Cancer Center, University of Minnesota

Katy Schroeder

Medical College of Wisconsin Cancer Center

Michael Steinberg, MD

UCLA Jonsson Comprehensive Cancer Center

Kristi Stiffler

Fred Hutchinson Cancer Center

Erin Williams, MBA

Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

FINANCE AND INVESTMENT**Chair: David M. Gosky, MA, MBA**

The Ohio State University Comprehensive Cancer Center -
James Cancer Hospital and Solove Research Institute

Julie Brabbs, MBA

University of Michigan Rogel Cancer Center

Patrick O'Brien, MBA

Fox Chase Cancer Center, Temple Health

Julia C. Schaum, MS

Vanderbilt-Ingram Cancer Center

Joanna Weiss, CPA

Moffitt Cancer Center

GOVERNMENT RELATIONS**Chair: Matthew Swaback, MHA**

Sidney Kimmel Cancer Center at Jefferson Health

Alexander R. Currie

Vanderbilt-Ingram Cancer Center

John DeMuro

Moffitt Cancer Center

James Kennedy

Roswell Park Comprehensive Cancer Center

Alex M. Krigstein

University of Florida Health Cancer Center

Catherine Liao

Duke Cancer Institute, Duke University Medical Center

Peter J. Mackler

City of Hope Comprehensive Cancer Center

Jill Homer Stewart

The Jackson Laboratory Cancer Center

**LEADERSHIP DIVERSITY AND
DEVELOPMENT INITIATIVE****Chair: Caryn Lerman, PhD**

USC Norris Comprehensive Cancer Center

David M. Gosky, MA, MBA

The Ohio State University Comprehensive Cancer Center -
James Cancer Hospital and Solove Research Institute

Chanita Hughes Halbert, PhD

USC Norris Comprehensive Cancer Center

Roy A. Jensen, MD

The University of Kansas Cancer Center

Kelvin Lee, MD

Indiana University Melvin and Bren Simon
Comprehensive Cancer Center

**Edith P. Mitchell, MD, MACP, FCPP, FRCP
(London)**

Sidney Kimmel Cancer Center at Jefferson Health

Kunle Odunsi, MD, PhD

The University of Chicago Medicine
Comprehensive Cancer Center

Jennifer W. Peger, MA, MBA

Association of American Cancer Institutes

Elisa Rodriguez, PhD, MS

Roswell Park Comprehensive Cancer Center

Yolanda Sanchez, PhD

University of New Mexico Comprehensive Cancer Center

Reuben J. Shaw, PhD

Salk Institute Cancer Center

Cornelia Ulrich, MS, PhD

Huntsman Cancer Institute at the University of Utah

George J. Weiner, MD

Holden Comprehensive Cancer Center
University of Iowa

Cheryl L. Willman, MD

Mayo Clinic Comprehensive Cancer Center

NOMINATING COMMITTEE**Chair: Carlos L. Arteaga, MD**

Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

Roy A. Jensen, MD

The University of Kansas Cancer Center

Joe W. Ramos, PhD

Louisiana Cancer Research Center

**PHYSICIAN CLINICAL LEADERSHIP
INITIATIVE (PCLI) STEERING COMMITTEE****Chair: Karen L. Reckamp, MD, MS**

Cedars-Sinai Cancer

Paula Fracasso, MD, PhD, FACP

VCU Massey Comprehensive Cancer Center

Carrie Lee, MD, MPH

UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Christopher Lieu, MD

University of Colorado Cancer Center

Stephanie Lim, MD, MBA

University of Hawai'i Cancer Center
University of Hawai'i at Mānoa

Quan P. Ly, MD, FACS

Fred & Pamela Buffett Cancer Center

Nicole Simone, MD

Sidney Kimmel Cancer Center at Jefferson Health

Julie Ann Sosa, MD, MA, FACS, MAMSE, FSSO

UCSF Helen Diller Family Comprehensive Cancer Center

Julie M. Vose, MD, MBA

University of Nebraska Medical Center

Theresa L. Werner, MD

Huntsman Cancer Institute at the University of Utah

Julia White, MD, FACR, FASTRO

The University of Kansas Cancer Center

Lee Wilke, MD

University of Wisconsin Carbone Cancer Center

**PCLI CANCER SERVICE LINE SURVEY
WORKING GROUP****Paula Fracasso, MD, PhD, FACP**

VCU Massey Comprehensive Cancer Center

Stephanie Lim, MD, MBA

University of Hawai'i Cancer Center
University of Hawai'i at Mānoa

Nicole Simone, MD

Sidney Kimmel Cancer Center at Jefferson Health

Lee Wilke, MD

University of Wisconsin Carbone Cancer Center

2023 MEMBERS



UNITED STATES

ALABAMA

O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham
Birmingham, Alabama

ARIZONA

Mayo Clinic Comprehensive Cancer Center, Arizona
Scottsdale, Arizona

The University of Arizona Cancer Center
Tucson, Arizona

ARKANSAS

UAMS Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas

CALIFORNIA

Cedars-Sinai Cancer
Los Angeles, California

City of Hope Comprehensive Cancer Center
Duarte, California

Loma Linda University Cancer Center
Loma Linda, California

Salk Institute Cancer Center
La Jolla, California

Sanford Burnham Prebys Medical Discovery Institute
La Jolla, California

Stanford Cancer Institute
Palo Alto, California

UC Davis Comprehensive Cancer Center
Sacramento, California

UC San Diego Moores Cancer Center
La Jolla, California

UCI Chao Family Comprehensive Cancer Center
Orange, California

UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California

UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

USC Norris Comprehensive Cancer Center
Los Angeles, California

COLORADO

University of Colorado Cancer Center
Aurora, Colorado

CONNECTICUT

**Yale Cancer Center
Yale School of Medicine**
New Haven, Connecticut

DISTRICT OF COLUMBIA

Georgetown Lombardi Comprehensive Cancer Center
Washington, District of Columbia

GW Cancer Center
Washington, District of Columbia

FLORIDA

Mayo Clinic Comprehensive Cancer Center, Florida
Jacksonville, Florida

Moffitt Cancer Center
Tampa, Florida

**Sylvester Comprehensive Cancer Center
University of Miami**
Miami, Florida

University of Florida Health Cancer Center
Gainesville, Florida

GEORGIA

Georgia Cancer Center, Augusta University
Augusta, Georgia

Winship Cancer Institute of Emory University
Atlanta, Georgia

HAWAII

**University of Hawai'i Cancer Center
University of Hawai'i at Mānoa**
Honolulu, Hawai'i

ILLINOIS

Cancer Center at Illinois
Urbana, Illinois

**Cardinal Bernardin Cancer Center
Loyola University of Chicago**
Maywood, Illinois

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois

**The University of Chicago Medicine
Comprehensive Cancer Center**
Chicago, Illinois

University of Illinois Cancer Center
Chicago, Illinois

INDIANA

**Indiana University Melvin and Bren Simon
Comprehensive Cancer Center**
Indianapolis, Indiana

**Purdue University Institute for
Cancer Research**
West Lafayette, Indiana

IOWA

**Holden Comprehensive Cancer Center
University of Iowa**
Iowa City, Iowa

KANSAS

The University of Kansas Cancer Center
Kansas City, Kansas

KENTUCKY

UK Markey Cancer Center
Lexington, Kentucky

UofL James Graham Brown Cancer Center
Louisville, Kentucky

LOUISIANA

Louisiana Cancer Research Center
New Orleans, Louisiana

LSU LCMC Cancer Center
New Orleans, Louisiana

MAINE

The Jackson Laboratory Cancer Center
Bar Harbor, Maine

MARYLAND

**Murtha Cancer Center at
Walter Reed Bethesda**
Bethesda, Maryland

**Sidney Kimmel Comprehensive Cancer Center at
Johns Hopkins University**
Baltimore, Maryland

**University of Maryland Marlene and Stewart
Greenebaum Comprehensive Cancer Center**
Baltimore, Maryland

MASSACHUSETTS

Boston University Cancer Center
Boston, Massachusetts

**Dana-Farber Cancer Institute
Harvard Medical School**
Boston, Massachusetts

**Koch Institute for
Integrative Cancer Research at MIT**
Cambridge, Massachusetts

MICHIGAN

**Karmanos Cancer Institute
Wayne State University**
Detroit, Michigan

University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

MINNESOTA

**Masonic Cancer Center
University of Minnesota**
Minneapolis, Minnesota

Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota

MISSISSIPPI

UMMC Cancer Center and Research Institute
Jackson, Mississippi

MISSOURI

Ellis Fischel Cancer Center
Columbia, Missouri

Siteman Cancer Center
St. Louis, Missouri



NEBRASKA

Fred & Pamela Buffett Cancer Center
Omaha, Nebraska

NEW HAMPSHIRE

Dartmouth Cancer Center
Lebanon, New Hampshire

NEW JERSEY

Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

NEW MEXICO

**University of New Mexico
Comprehensive Cancer Center**
Albuquerque, New Mexico

NEW YORK

Cold Spring Harbor Laboratory Cancer Center
Cold Spring Harbor, New York

**Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center**
New York, New York

**Laura and Isaac Perlmutter Cancer Center at
NYU Langone**
New York, New York

Memorial Sloan Kettering Cancer Center
New York, New York

**Montefiore Einstein
Comprehensive Cancer Center**
Bronx, New York

Northwell Health Cancer Institute
Lake Success, New York

Roswell Park Comprehensive Cancer Center
Buffalo, New York

**Sandra and Edward Meyer Cancer Center at
Weill Cornell Medicine**
New York, New York

Stony Brook Cancer Center
Stony Brook, New York

The Tisch Cancer Institute at Mount Sinai
New York, New York

**Upstate Cancer Center
SUNY Upstate Medical University**
Syracuse, New York

**Wilmot Cancer Institute
UR Medicine**
Rochester, New York

NORTH CAROLINA

**Atrium Health Wake Forest Baptist
Comprehensive Cancer Center**
Winston-Salem, North Carolina

**Duke Cancer Institute
Duke University Medical Center**
Durham, North Carolina

**UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill**
Chapel Hill, North Carolina

OHIO

Case Comprehensive Cancer Center
Cleveland, Ohio

Cleveland Clinic Cancer Center
Cleveland, Ohio

**The Ohio State University
Comprehensive Cancer Center -
James Cancer Hospital and
Solove Research Institute**
Columbus, Ohio

University of Cincinnati Cancer Center
Cincinnati, Ohio

OKLAHOMA

**Stephenson Cancer Center
University of Oklahoma**
Oklahoma City, Oklahoma

OREGON

OHSU Knight Cancer Institute
Portland, Oregon

PENNSYLVANIA

**Abramson Cancer Center of the
University of Pennsylvania**
Philadelphia, Pennsylvania

**Ellen and Ronald Caplan Cancer Center of
The Wistar Institute**
Philadelphia, Pennsylvania

**Fox Chase Cancer Center
Temple Health**
Philadelphia, Pennsylvania

Penn State Cancer Institute
Hershey, Pennsylvania

**Sidney Kimmel Cancer Center at
Jefferson Health**
Philadelphia, Pennsylvania

UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

PUERTO RICO

**University of Puerto Rico
Comprehensive Cancer Center**
San Juan, Puerto Rico

RHODE ISLAND

Legorreta Cancer Center at Brown University
Providence, Rhode Island

SOUTH CAROLINA

**Hollings Cancer Center
Medical University of South Carolina**
Charleston, South Carolina

TENNESSEE

**Comprehensive Cancer Center
St. Jude Children's Research Hospital**
Memphis, Tennessee

Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

TEXAS

**Dan L Duncan Comprehensive Cancer Center at
Baylor College of Medicine**
Houston, Texas

**Houston Methodist Dr. Mary and Ron Neal
Cancer Center**
Houston, Texas

**Livestrong Cancer Institutes
The University of Texas at Austin
Dell Medical School**
Austin, Texas

**Mays Cancer Center at
UT Health San Antonio MD Anderson**
San Antonio, Texas

**Simmons Comprehensive Cancer Center
UT Southwestern Medical Center**
Dallas, Texas

**The University of Texas MD Anderson
Cancer Center**
Houston, Texas

**University of Texas Medical Branch
Cancer Center**
Galveston, Texas

UTAH

**Huntsman Cancer Institute at the
University of Utah**
Salt Lake City, Utah

VERMONT

The University of Vermont Cancer Center
Burlington, Vermont

VIRGINIA

University of Virginia Cancer Center
Charlottesville, Virginia

VCU Massey Comprehensive Cancer Center
Richmond, Virginia

WASHINGTON

Fred Hutchinson Cancer Center
Seattle, Washington

WEST VIRGINIA

WVU Cancer Institute
Morgantown, West Virginia

WISCONSIN

Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin

University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

CANADA

BRITISH COLUMBIA

BC Cancer
Vancouver, British Columbia

ONTARIO

**Princess Margaret Cancer Centre
University Health Network**
Toronto, Ontario



PO Box 7317
Pittsburgh, PA 15213

www.aaci-cancer.org

